Cin Nasara a Cikin Maganin CAR-T Don Ciwon Daji na T-Cell

Maganin T-cell na Chimeric Antigen Receptor (CAR-T) ya tabbatar da cewa magani ne mai matuƙar amfani ga cututtukan jini da aka samo daga ƙwayoyin B, yana ba da inganci da aminci mai yawa. Duk da haka, ana amfani da shi ga cututtukan T-cell, kamar cutar sankarar lymphoblastic mai saurin kamuwa da cutar T-cell (T-ALL) da kuma na gefe. Lymphoma na T-Cell (PTCL), yana gabatar da manyan ƙalubale. Ɗaya daga cikin manyan ƙalubalen yana cikin kamanceceniya tsakanin ƙwayoyin T masu cutarwa da ƙwayoyin T na yau da kullun, wanda hakan ke sa ya zama ƙalubale a kai hari ga ƙwayoyin cutar kansa kawai ba tare da lalata ƙwayoyin T masu lafiya ba. Wannan yana haifar da wani abu da aka sani da "fratricide," inda ƙwayoyin CAR-T ke kai hari ga ƙwayoyin T masu cutarwa da na yau da kullun, wanda hakan ke takaita tasirin maganin sosai. Bugu da ƙari, bambancin ƙwayoyin T masu cutarwa yana rikitar da gano abubuwan da ƙwayoyin CAR-T ke hari a duniya, saboda antigen guda ɗaya da aka yi niyya ba za a iya bayyana shi iri ɗaya a cikin dukkan ƙwayoyin cutar kansa ba.

A gwaje-gwajen asibiti, ƙwayoyin CAR-T da ke kai hari ga ƙwayoyin T kamar CD5 da CD7 sun nuna ɗan nasara wajen magance cututtukan T-cell. Waɗannan abubuwan da ake hari ana samun su ne a saman yawancin cututtukan T-cell, amma kuma suna bayyana a kan ƙwayoyin T-cell na yau da kullun, wanda ke haifar da mummunan sakamako kamar raguwar ƙwayoyin T, ƙarancin garkuwar jiki, da ƙaruwar saurin kamuwa da cututtuka. Don rage waɗannan ƙalubalen, masu bincike suna mai da hankali kan takamaiman ƙwayoyin T-cell da aka “ƙayyade”, kamar CD4, CD30, CD37, da CCR4. Waɗannan ƙwayoyin T-cell sun fi zaɓar wasu ƙananan ƙwayoyin T, waɗanda za su iya rage haɗarin fratricide da kuma kiyaye aikin rigakafi na yau da kullun. Duk da haka, binciken da aka yi kan waɗannan ƙwayoyin antigen da aka takaita har yanzu yana kan matakai na farko, kuma zaɓin marasa lafiya da kyau yana da mahimmanci don tantance mafi dacewa ga kowane lamari.

Wata dabarar da ake bincike a kanta ta ƙunshi haɓaka ƙwayoyin CAR-T na allogeneic, waɗanda aka samo daga masu ba da gudummawa masu lafiya maimakon marasa lafiya da kansu. Ana iya gyara ƙwayoyin CAR-T na allogeneic ta hanyar halitta don hana gurɓatar ƙari da rage haɗarin cutar dashen-dashe-dashe (GvHD), wata matsala da aka saba fuskanta a saitunan dashen. Duk da haka, waɗannan ƙwayoyin suna fuskantar ƙalubale kamar ƙin yarda da garkuwar jiki, wanda zai iya iyakance tasirinsu na dogon lokaci. Don magance wannan, ana binciken dabarun gyara kwayoyin halitta kamar CRISPR/Cas9 da gyaran tushe don gyara ƙwayoyin CAR-T, wanda hakan zai sa su zama masu amfani a duk duniya kuma su fi aminci ga marasa lafiya. Gyaran tushe, musamman, yana ba da madadin gyaran kwayoyin halitta na gargajiya, saboda yana guje wa haɗarin da ke tattare da karyewar DNA mai nau'i biyu, rage gubar kwayoyin halitta da inganta yanayin aminci na magungunan CAR-T.

Duk da waɗannan ci gaban, akwai ƙalubale da dama da suka rage. Kwayoyin CAR-T ba sa iya riƙe dawwama na dogon lokaci a jiki, wanda zai iya haifar da sake dawowar cututtuka. Bayan magani da ƙwayoyin CAR-T da aka yi niyya ga CD7, misali, ƙwayoyin T-negative na CD7 na iya fitowa kuma su tsayayya wa kisan ƙwayoyin CAR-T, wanda ke ƙara rikitar da maganin. Masu bincike suna binciken hanyoyin inganta tsawon rai da ingancin ƙwayoyin CAR-T, gami da haɗa maganin CAR-T tare da wasu jiyya, kamar dashen ƙwayoyin tushe, don ƙarfafawa da kuma kiyaye gafara. Wannan hanyar, wacce aka sani da "maganin haɗin gwiwa," na iya samar da ƙarin kariya daga sake dawowa, musamman a cikin marasa lafiya da ke da nauyin ƙari mai yawa.

Matsalolin da ke biyo bayan maganin CAR-T, gami da cutar sakin cytokine (CRS), cutar neurotoxicity da ke da alaƙa da garkuwar jiki (ICANS), da kuma kamuwa da cuta ta dama, suma suna cikin abubuwan da ake damuwa da su. Musamman raguwar ƙwayoyin T, yana barin marasa lafiya cikin haɗarin sake kunna cututtukan da ba a san su ba kamar kwayar cutar Epstein-Barr (EBV) da cytomegalovirus (CMV), yayin da danne ƙashi na iya haifar da tsawaitar cytopenia. Don rage waɗannan haɗarin, masu bincike suna binciken hanyoyin inganta aminci da ingancin ƙwayoyin CAR-T, kamar gabatar da maɓallan tsaro da amfani da gajerun hanyoyin magani don rage tasirin da ke tattare da su.

Gabaɗaya, yayin da maganin CAR-T ya sami ci gaba mai mahimmanci a cikin maganin cututtukan jini na ƙwayoyin T, ƙalubalen da suka shafi niyya ga antigen, rikice-rikicen tsarin garkuwar jiki, da juriya na dogon lokaci har yanzu suna nan. Ci gaba da bincike da ƙirƙira a cikin fasahar CAR-T, gami da haɓaka magungunan da aka yi niyya biyu, dabarun gyara kwayoyin halitta, da kuma zaɓin marasa lafiya daidai, suna da mahimmanci don buɗe babban yuwuwar maganin CAR-T wajen magance cututtukan ƙwayoyin T. Yayin da gwaje-gwajen asibiti ke ci gaba da bincika sabbin dabaru, fatan shine maganin CAR-T zai haɓaka don samar da zaɓuɓɓukan magani masu ɗorewa da aminci ga marasa lafiya da ke fama da waɗannan cututtukan daji masu ƙalubale.